Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://www.inergetics.com/cbd-initiative/
"THE CBD INITIATIVE
As a leader in nutraceutical development, Inergetics is launching the CBD Initiative focused on exploring the growth, extraction and development of cannabinoid based nutritional products. While THC (tetrahydrocanabinol) found in medical marijuana was the focus of attention in the past, evolving research on other non-psychoactive cannabinoids such as CBD (cannabidiol) addressing a variety of clinical conditions including pain, nausea, seizures, eye and brain health are on the forefront of evidenced based medicine and nutritional science. Acknowledging the wealth of published data unraveling the medical benefits of cannabinoids, Inergetics plans to be a leader in providing various marketplaces with pharmaceutical grade nutritional products.
Helping us to better understand cannabinoids and the advances that are taking place in the laboratory and physician’s office, Inergetics has assembled a collective of accomplished physicians and PhD’s to man its Medical/Scientific Advisory Board. With much of the new literature aimed at advances in laboratory techniques for isolation, detection and extraction of cannabinoids; awareness of the various cannabinoids expressing therapeutic effects; and clinical application, we look forward to our Board to provide their experience and insights to help guide us in our product development.
Inergetics is proud to work with its strategic partner Terra Tech (TRTC) to embark on the CBD Initiative to provide patients and consumers the first comprehensive line of CBD-based nutraceuticals.
ADVISORY BOARD
Carl Germano, RD, CNS, CDN
Chief Science Officer, Research & Product Development
As Chief Science Officer for Inergetics, Mr. Germano is a Board Certified Clinical Nutritionist and Registered Dietician with over 30 years’ experience using innovative, complementary nutritional therapies in private practice and in product development. He holds a Master’s degree in clinical nutrition from New York University and has dedicated his efforts to research and new product development for the nutritional industry (medical foods, dietary supplements and functional beverages), where he has been instrumental in bringing over state-of-the-art nutritional ingredients and over 200 nutritional formulations to market. Mr. Germano continues his efforts in new product development at Inergetics and is responsible for providing the company with the next generation of clinically relevant ingredients and formulations. He has also held a progressive Nutrition Therapy Center practice for many years and has extensive experience in the nutritional treatment of disease.
In addition to his vast clinical experience, he has served as a VP of R&D or as new product development consultant for some of the largest dietary supplement companies in the industry, including Solgar Vitamin & Herb Company, Bluebonnet Nutrition, Ajinomoto’s Amino Vital, Isocell, Nutratech and Country Life Vitamins. He recently launched his new book The Misled Athlete and is also the author of the best selling trade books: Natures Pain Killers, The Osteoporosis Solution and The Brain Wellness Plan and is a frequent featured radio guest.
Joseph McSherry, MD
Dr. McSherry is a neurologist who has extensive knowledge of research involving the medical benefits of cannabis and its cannabinoids for pain management, medicinal and therapeutic use. He is a widely recognized academic expert on medical cannabis/cannabinoids and its many health benefits, and is also involved in several community service initiatives including his service on the State of Vermont’s Marijuana Oversight Committee. Dr. McSherry is the author of numerous academic and public presentations on the medical use of cannabis/cannabinoids in general and as it relates to cancer and other specific medical conditions. He received the Outstanding Physician Advocate Award from the Washington, D.C.-based Marijuana Policy Project in 2010.
Dr. McSherry is a practicing physician licensed in both Vermont and New York, currently serving as an Attending Neurologist at Fletcher Allen Health Care in Burlington, Vermont. Additionally, he serves as a Clinical Associate Professor of Neurology at the University of Vermont, College of Medicine, where he has been teaching since 1977. He previously served as the Associate Medical Director of Blue Cross Blue Shield of Vermont, and as Assistant Professor of Neurology at Baylor College of Medicine in Houston, Texas.
Dr. McSherry received his B.A. from Harvard College in Cambridge, Massachusetts, and his M.D. and Ph.D. from Baylor College of Medicine in Houston, Texas. He is a member of the American Academy of Neurology, the American Clinical Neurophysiology Society, the Eastern EEG Society, the Northern New England Neurological Society and the Vermont Medical Society. In addition, Dr. McSherry is board certified by the American Board of Clinical Neurophysiology, the American Board of Psychiatry & Neurology, with Added Qualification in Neurophysiology, as well as the Part I Academy for Healthcare Management.
Mark Wallace, MD
Dr. Wallace is an acclaimed anesthesiologist specializing in pain management, with deep experience researching innovative pain treatments and performing in-depth clinical trials on all types of pain. He is board certified in both anesthesiology and pain medicine in the State of California, and is on faculty at the University of California San Diego Health System and the Veterans Affairs San Diego Healthcare System.
At UC San Diego, Dr. Wallace serves as the chair of the Division of Pain Medicine and is a Professor of Clinical Anesthesiology. He is also the Director, Division of Clinical Research, UCSD Clinical and Translational Research Institute. He is actively involved in all aspects of clinical care, graduate medical education/training and research. Dr. Wallace’s research on pain medicine has been widely published in an extensive array of peer-reviewed medical journals and books. He is also the recipient of numerous grants, including grants from Pfizer, Medtronic and Abbott.
Dr. Wallace is a Diplomate of the American Board of Pain Medicine, the American Board of Anesthesiology and the National Board of Medical Examiners. He is also on the Board of Directors of the American Pain Society, and a member of several other professional societies including the American Academy of Pain Medicine and the International Association for the Study of Pain, among others. From 2010 to 2013, Dr. Wallace was named “Top Doc” in San Diego Magazine’s “Physicians of Exceptional Excellence” annual survey performed in collaboration with the San Diego County Medical Society. He was also the recipient of the Leonard Tow Humanism in Medicine Award in 2012.
Dr. Wallace earned his M.D. from Creighton University School of Medicine, completed his residency in anesthesiology at the University of Maryland and also completed a NIH Training Grant Fellowship and a Pain Fellowship at the University of California, San Diego.
Michelle Sexton, ND
Dr. Sexton is a highly-respected expert in the medicinal applications of cannabis, naturopathic medicine and the phytochemistry of plant medicine, with more than 15 years of experience in natural, herbal and holistic medicine. She currently serves as the Executive Medical Research Director at the Center for the Study of Cannabis and Social Policy in Seattle. For the past several years, she owned and operated Phytalytics LLC, doing business as PhytaLab, a phytochemical analysis company dedicated to developing and perfecting analytical platforms for the quality control of medical and adult use cannabis and related products in Washington State.
Dr. Sexton is an active authority on medical cannabis, having published research in scientific journals, presented a number of abstracts on the medical application of cannabis and cannabinoids, particularly for patients with multiple sclerosis, provides continuing education for healthcare providers on the clinical use of Cannabis, and serves as an expert witness for medical cannabis cases. She is a member of the Society of Cannabis Clinicians, the International Cannabinoid Research Society (ICRS), and the International Association for Cannabinoid Medicine (IACM). She is on the board of directors for Americans for Safe Access Foundation.
Dr. Sexton earned her B.S. in Horticulture from Texas Tech University, graduating cum laude. She received her doctorate in Naturopathic Medicine from Bastyr University in Seattle, Washington, and completed her postdoctoral fellowship at the University of Washington.
Justin Fischedick, PhD
Dr. Fischedick is a respected expert in the therapeutic and medicinal properties of the chemical components of plants, specifically cannabis. He brings years of experience in advanced chromatography and spectrometry, including proven abilities in the isolation of natural products for scientific and medical analysis.
Dr. Fischedick is currently a Postdoctoral Research Associate at the Institute of Biological Chemistry at Washington State University, and has authored or co-authored several scientific articles on cannabis, cannabinoids and terpenoids published in top scientific and medical journals. He has presented his scientific research at a number of national and international conferences including the Phytochemical Society of North America conference, the International Conference on Natural Products Research and the International Association for Cannabinoids as Medicine (IACM) conference.
Dr. Fischedick is also a member of the Phytochemical Society of North America, the Society for Medicinal Plant and Natural Products Research and the Central New York Mycological Society. He earned his B.S. in Biology from the State University of New York College of Environmental Science and Forestry (SUNY-ESF), and his M.Sc. and Ph.D. in Biology with a focus on Natural Products from the Leiden University, Institute of Biology in The Netherlands.
Yu Shao, PhD
Dr. Shao has extensive experience in product research and development across many areas of health and wellness, specializing in pharmaceutical extraction methods and plant biochemistry – as well as formulating herbal and botanical nutritional products. He brings almost two decades of expertise in these fields working with a variety of global firms, including Glaxo Smith Kline, Wyeth (now Pfizer), and Merck, directing the launch of more than 30 innovative new products for these companies.
Dr. Shao has an impressive record of isolating and extracting new herbal, vitamin and pharmaceutical products to market. His recent experience includes eight product launches in eight years at Glaxo Smith Kline U.S. and 25 new products in four-plus years at Glaxo Smith Kline China. He has served in a range of senior R&D roles during his 13-year career at Glaxo Smith Kline, including Head of R&D for the Consumer Healthcare business in China; Group Leader/Director, New Weight Loss Product Development; Principal Scientist, Smoking Control/Pain Management; and Senior Development Scientist. Dr. Shao has also served as Manager of Herbal and Vitamin R&D at Wyeth (now Pfizer) and as a Senior Scientist developing botanical extracts for dietary supplements at Pure World Botanicals. Additionally, he is the inventor and author of more than 60 pharmaceutical patents.
Dr. Shao received his Ph.D. in Natural Products Chemistry from the Shanghai Institute of Materia Medica, his M.A. in Organic Chemistry from Lanzhou University and his B.S. in Chemistry from Yangtze University. He also served as a Postdoctoral Fellow in Natural Products Chemistry at Rutgers University."
Lol ok. Look at the quality of experience of the medical board at Inergetics and then make your own claims.
Monestly, today was a good day! Looking for some similar action next week!
Most investors here are aware that Phil Frost has made an investment in another TRTC partner, VAPOD. VAPOD is also in another partnership to start adding B vitamins and other ingredients to certain vaporizers because of the documented health benefits of being able to ingest medicine by vapor. If you look into Frost's background, you will see its in healthcare, not tobacco. I'm curious to see if NRTI starts working closer with VAPOD to get their CBD medicine in the vaporizer market as well as in pill form through dispensaries. Considering James' involvement with these companies, there are a lot of really interesting potential scenarios with this medicine.
My favorite part about today (other than the price appreciation) was the outstanding volume. 3x avg. looking forward to next week, looks like there are a lot of new investors finally hearing about NRTI. Like liodog I think some news about a resolution regarding Martha's royalty and the convertible debt will really help this fly. Those two things I think are still holding the stock price back even though the company is executing and rubber is finally hitting the road.
Oh no!?!?!? They are diseased!?Maybe you're next email should be to the FDA!!!!
Is it me or did those plants look fine? How come you didn't include the competitors displays in the video?
NEWARK, N.J., Sept. 17, 2014 /PRNewswire/ -- Inergetics, Inc. (NRTI), a leading developer of nutritional supplements, today congratulates professional surfer Anastasia Ashley on her feature in Maxim magazine's October issue. The issue is on newsstands now.
"We are extremely proud that Maxim has recognized Anastasia Ashley for the same qualities that make her a perfect spokeswoman for Bikini Ready®: her athletic ability, commitment to fitness and sex appeal," said Jim Kras, Chief Marketing Officer of Inergetics. "Not only will Anastasia attract considerable attention from Maxim's male readers – she will inspire young women to get fit and live a healthy lifestyle. Maxim magazine is known for featuring the world's most gorgeous women, and we are thrilled that it is now showcasing Anastasia's inspiring talent and stunning Bikini Ready shape to its millions of readers."
Anastasia Ashley is one of the top surfers on the professional circuit today, with a long list of awards and accomplishments. In addition, she has built a large social media presence attracting over 500,000 followers. Her appearance in Maxim furthers an already exciting year that included her modeling for the 2014 Sports Illustrated Swimsuit issue. Additionally, she has previously been featured on television programs for MTV, ESPN, Access Hollywood and FX, as well as media outlets including Shape, Self, Sports Illustrated, Huffington Post, and GQ.
For more information on the full line of Bikini Ready products, including an exclusive video in which Anastasia discusses how Bikini Ready fits with her lifestyle and fitness regime, please visit www.bikinireadylifestyle.com/.
Inergetics Media Contact
KARV Communications
Jonathan Leibowitz
(212) 333-0273
Inergetics@KARVCommunications.com
About Inergetics, Inc.
Inergetics' portfolio of brands includes: Martha Stewart™ Essentials, a complete line of whole-food-based supplements created specifically for women; Surgex ® Sports Nutrition, the preferred nutritional supplement of Army Sports; Bikini Ready ®, a leader in weight loss lifestyle solutions; SlimTrim, the affordable, premium value diet brand; and OmEssentials®, a line of scientifically advanced nutritional supplements designed to further the health and wellness of yoga practitioners and active individuals.
If something did $8M in revenue annually and the original investment was $6M, wouldn't that be a good investment?
I'm happy to be long as well. Don't forget frost was one of the investors who got in from the transaction filed on the 29th at .11 or 5.50 so the fact that it's at 3.59 or .0718 means it's still a great opportunity to get in at a discount.
Those are all common disclosures of OTC companies that you found in the risk disclosures of the company in the 10-K or 10-Q. Please show me one OTC company who is not yet cash flow positive that doesn't have this kind of disclosure.
I had a friend at the Aegis Conference who took some short-hand notes of the Vaporin presentation yesterday morning. I'm not going to disclose any other information about the friend or myself. Take it for what it's worth but here is a copy of the notes:
"Does only vaporizers and liquids not e-cig
Did a 1 for 50 reverse split
Sells in convenience stores and online, vending machines in strip clubs and night clubs
Bought brick and mortar “the vape shops”
600k rev in 5 months 2014
40% margin
Also into Canabis line of vape
Vaporizers are better than e-cig, blue cig lost 35% share last quarter as people switch to vape from e-cig
Better hit and more volume more battery power and more types of liquids with vape
30,000 vape shops are in the us currently (not VAPO’s)
Chroma Dex supply agreement to add B3 vitamins and energy into the liquids
The pres of vapo had a manufacturing facility in China and lives there so he had a leg up in getting this manufactured in china and done correctly, cheaply, and with quality.
NY state passed law ok for medical marijuana, but only through vape or edible
They are headquartered in the same building as phil frost in Miami"
Thanks that makes a lot of sense. Especially with all the false fraud accusations against DP and his wife...hopefully we bounce back on some good news and an update on the tort suit
Every company that issues equity uses shareholders as an ATM. Every company that issues debt uses creditors as an ATM.
I agree. This gets the share price to a level where they can reasonably up-list which is one of the CEO's stated goals for the year. They also have a more attractive O/S for institutional investors. Combined with the Aegis conference tomorrow, I think things are headed in the right direction. Check tweets from Aegis Capital from yesterday that talk about VAPOs presentation and new technology.
"The wheels of justice turn slowly, but grind exceedingly fine" Looking forward to the multitude of catalysts coming this fall.
Nominally, the price will go up. The value of the shares will remain the same.
Lol big companies don't need to conduct dilution at the same rates as micro caps because they can get more favorable financing with better credit ratings.
In the fins you will also see the CEO makes $150k a year. Do the math on what his current shares are worth at these prices. By owning more shares and taking a discounted salary, he is incentivized to increase the share price so his goals align with the shareholders. The guy is mid 50's and has stated he's looking to retire soon. He's already turned around a failing company before selling it, which is what he was brought in to do here. If you take the time to read the financials you'll see he's done everything possible to avoid dilution including getting $5M in grants by relocating HQ. The huge A/S was already implemented by the CEO before James but the O/S is still not out of control. Dilution is something that has to happen with all companies at this level because of a lack of more attractive financing. This will change hopefully as sales improve with such great margins.
He is also a CPA. Pretty sure he has a clue what's going on. Here is his bio:
Mr. Michael C. James, CPA, is Chief Financial Officer at Terra Tech Corp., Chairman, Chief Executive & Financial Officer at Inergetics, Inc., Chairman at Guided Therapeutics, Inc., a Managing Director at Kuekenhof Partners LP, a Managing Director at Kuekenhof Equity Fund LP, and Managing Partner at Kuekenhof Capital Management LLC.
Mr. James was previously employed as Chairman & Chief Executive Officer by Nestor, Inc., Partner by Moore Capital Management LP, Chief Financial & Administrative Officer by Buffalo Partners LLC, Chief Financial Officer & Treasurer by National Discount Brokers Group, Inc., Staff Accountant by Eisner LLP, and a Portfolio Manager by FirstMerit Trust.
He received his undergraduate degree from Fairleigh Dickinson University.
They could also do a reverse split couldn't they? After GOOG winning by fighting like a 4yr old that needs a nap, Idk how much vrng could get from ZTE if they go that route as well.
Agreed. I think next week at those conferences we may hear of additional test locations and also an update on the readiness to begin tests. After this much time, it's my opinion that they've had ample time to train and equip the locations that have been disclosed and those locations may just be waiting for a qualified subject (as dark and unemotional as that may sound).
NVIV not only needs people who have had serious injuries but the timing of these injuries is also crucial. With the FDA approval, NVIV will be able to tell us when the first patient is enrolled and gives us updates on progress quickly.
Lol I don't own it. Just don't understand the point of patting yourself on the back and rubbing everyone else's face in it. People get it. You win. Get over yourself
What was the point of that post? Do you want applause?
I don't think there's anyone here who's not impressed by your dedication. I love learning the same things about TRTC every 2 hours, but new material wouldn't hurt either... Best of luck!
Couldn't agree more! Hahaha
Thank you ziggy glad to see you hear too
Listen to the 90 minute interview DP gave last week on 420 investor he answered all the scam questions which are all false and also talks about the lawsuit. Maybe if you heard it directly from the source your "opinion" will change
This article has been posted repeatedly over and over and over. TRTC is suing them for tortious interference. The whole article is full of half truths with an incredibly biased twist. My opinion is you need to get over yourself. Your liar/opinion posts are full of semantics. Call it what you want but you aren't the victim here. You are now trying to spread misinformation.
This board reminds me of the really annoying mosquitoes in my backyard during monsoon season that do nothing beneficial but leave the worst itching bite just to remind me that they are around. Maybe NRTI will make a version of CBD supplements to help with my mosquito problems.
WRAY, Colo. — Behind a tall curtain of corn that hides its real cash crop from prying eyes, the Stanley family is undertaking an audacious effort to expand its medical marijuana business to a national market.
For years, the five Stanley brothers, who sell a nonintoxicating strain of cannabis that has gained national attention as a treatment for epilepsy, have grown medical marijuana in greenhouses, under tight state and federal regulations.
But this year, they are not only growing marijuana outdoors by the acre, they also plan to ship an oil extracted from their plants to other states.
The plan would seem to defy a federal prohibition on the sale of marijuana products across state lines. But the Stanleys have justified it with a simple semantic swap: They now call their crop industrial hemp, based on its low levels of THC, the psychoactive ingredient in marijuana.
“The jump to industrial hemp means we can serve thousands of people instead of hundreds,” said Jared Stanley, 27, who wore muddy Carhartts and a rainbow friendship bracelet as he knelt down to prune his plants.
Colorado, which has legalized the sale of marijuana for recreational and medical use, has accepted the new designation. But the real question is whether the federal government will go along. If it does, the impact would be significant, opening the door to interstate sales not just by the Stanleys, but possibly by scores of other medical cannabis growers across the country.
But if it does not, the Stanley brothers could be shut down by federal agents.
So far, the Drug Enforcement Administration is offering few clues, insisting in public statements that while it is willing to allow marijuana sales in states that have legalized the drug, it might step in if growers try to sell beyond state borders.
“Any chemical that comes from the plant is still a controlled substance,” said Dawn Dearden, an agency spokeswoman. “When we get into hemp, it gets a little squishy, but it still is illegal.”
The Stanleys’ quest to ship their oil to other states highlights the fraught marijuana legal landscape where state and federal laws conflict and federal agencies can have divergent policies, leaving laws sometimes enforced, and sometimes not.
“This is the mode we will be in for some time,” said Sam Kamin, a law professor at the University of Denver who studies cannabis law. “As marijuana becomes more legal in more states for more purposes, the tension with the federal law will become more pronounced.”
The hazy legality of hemp can be seen in products like hemp granola and shampoo, which are allowed to fill health food store shelves even though they technically violate federal drug laws. All those products are made from imported hemp, which has generally been permitted into the country so long as it has less than 0.3 percent THC.
If the Stanleys ship their oil, industry watchers say, it will be the first time in decades anyone has tried to sell domestic hemp nationwide.
In recent years, hundreds of families with children who have epilepsy have moved to Colorado to try oil made from the Stanleys’ shrubby strain, which they call Charlotte’s Web. The national Epilepsy Foundation has called for it to be available to all patients, although formal research into its effectiveness remains scant. There is a nationwide waiting list of more than 9,000, which the brothers hope to eliminate by expanding their crop from small greenhouses into vast hemp fields.
“We are hoping the enforcement agencies have bigger fish to fry and don’t want to take a bunch of medicine away from sick kids,” Stanley said. “But if they are going to do it, we’re all in. If you are going to be locked up, it’s a thing worth getting locked up for.”
The brothers, who had a Christian upbringing in conservative Colorado Springs, started a small medical marijuana business in 2008 after seeing the relief it brought to a relative sick with cancer. At first, they grew mostly marijuana high in THC that packed a serious psychoactive punch.
On the side, they experimented with breeding plants low in THC but high in another cannabinoid known as cannabidiol, or CBD, which scientific studies suggested was a powerful antiinflammatory that a handful of small studies showed might have potential as a treatment for certain neurological conditions, including seizures and Huntington’s disease.
Oh so you were blaming him on behalf of the nameless investors who lost with you?
Really? "If anyone is a liar here it is you. People who have been listening to your constant pumping are down huge. I thought you were onto something and I actually believed you back when the stock was at $0.30... well guess that the stock has lost 90% since then and it's getting worse."
Lol. It's not his fault you had a stock alert for penny stocks and bought at the highs. He actually said he was selling when it went up that much and he's been buying back at these rock bottom prices. It takes a little skill to make money liodog. Can't fly blind and pray. CN almost every post also says to do your own DD so not sure how it's his fault you had awful timing. Everything with the company is still intact, this is penny land. Things get volatile.
CN, VERY happy to see bikini ready being carried by bodybuilding.com like we had talked about over the summer! That is a HUGE online sales opportunity as even on their home page it states they are the #1 online supplement store with over 20 million orders shipped. I personally order from them regularly and have never received a package with standard shipping in less than three days.
Thank you. 10-Q's that you're referencing are very important, maybe most important, but they are not the only sources of factual information and they don't tell you what is happening currently.
I honestly don't give 2 sh!!ts about how anyone feels. I invest to make money. Period. I didn't take the time to read your whole post but the difference between a positive post with facts and a negative post with zero value about someone WHINING how far it's gone down or that the company is "terrible" is that I can separate the facts out from positive sentiment and read what is actually happening so I can form MY OWN OPINIONS on what I'm going to do with my money that I work hard for.
Would you come out and publicly refute anything if your lawyers were telling you to be quiet because the violators are still producing more evidence on a regular basis??? I would suggest listening to Derek Peterson's interview. It's crazy how many of your questions were answered by the man himself in 90 minutes.
Just to save some time for you, one if the Clark county commissioners is willing to testify on TRTC's behalf that she withdrew her vote for the dispensary permit based on the information that was sent to her. She would have been the 3rd and final vote needed for TRTC's approval and in the next meeting the public expressed their outrage that TRTC was not given a dispensary permit.
The Clark county commissioner's counsel has also turned over all of those documents to TRTC's counsel. A civil suit is expected to be filed in the next 60 days.
It sure sounds like TRTC not only has LPR, but also his Canadian hedge fund buddies that he so proudly talks about.
Robin, posts like the one I'm replying to that have negative sentiment and include personal attacks without any factual contribution are why people with negative sentiment get blasted on a general basis. People that invest in a company tend to do their own research which is also why a lot of positive posts included cited facts with personal projections on what the facts state. Like you said, NRTI seems to be in an advantageous position moving forward.
If you think there's a correlation between what anyone says on a message board and the price of a security then you probably should stick with mutual funds or ETFs anyways, to be honest.
Can TRTC make that interview a press release? I'm concerned that not even all of the 25,000 shareholders know about it, let alone potential new investors. There was a lot of great info in the interview and there is no news about it on the terminals at work.